Related Experiment Video

Updated: May 8, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Emerging Roles of SIRT1 in Cancer Drug Resistance

Zhiqiang Wang1, Wenyong Chen

  • 1Department of Cancer Biology, Beckman Research Institute, City of Hope, Duarte, CA, USA.

Genes & Cancer
|September 11, 2013
PubMed

Insights

Sirtuin 1 (SIRT1) is a key factor in cancer drug resistance, promoting survival and hindering treatment efficacy. Targeting SIRT1 offers a promising strategy to overcome resistance and improve cancer therapy outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cancer drug resistance is a major clinical challenge, limiting the effectiveness of targeted therapies.
  • Acquired resistance mechanisms in cancer involve complex cellular and environmental factors.
  • The mammalian stress response gene, sirtuin 1 (SIRT1), is increasingly implicated in cancer progression and treatment resistance.

Purpose of the Study:

  • To review current research on the role of SIRT1 in various forms of cancer drug resistance.
  • To elucidate the multifaceted mechanisms by which SIRT1 contributes to therapeutic failure.
  • To highlight the potential of targeting SIRT1 as a novel strategy to enhance cancer treatment.

Main Methods:

  • Literature review of preclinical and clinical studies investigating SIRT1 in cancer.
  • Analysis of molecular and cellular mechanisms underlying SIRT1-mediated drug resistance.
  • Evaluation of therapeutic strategies targeting SIRT1 in preclinical cancer models.

Main Results:

  • SIRT1 promotes cancer drug resistance by reducing drug penetration and conferring survival advantages.
  • SIRT1 facilitates acquired resistance through genetic mutations and supports cancer stem cell survival.
  • SIRT1 influences the tumor microenvironment, contributing to both cell-autonomous and non-autonomous resistance.

Conclusions:

  • SIRT1 is a critical mediator of innate and acquired resistance to cancer therapies.
  • Targeting SIRT1 presents a viable therapeutic avenue to overcome drug resistance.
  • Further research into SIRT1 inhibition may lead to improved cancer treatment strategies and patient outcomes.
Keywords:
SIRT1acquired resistancecancer stem cellsdrug resistancegenetic mutationtumor microenvironment

More Related Videos

Deacetylation Assays to Unravel the Interplay between Sirtuins (SIRT2) and Specific Protein-substrates14:32

Deacetylation Assays to Unravel the Interplay between Sirtuins (SIRT2) and Specific Protein-substrates

Published on: February 27, 2016

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...